Stoke Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

• Stoke Therapeutics Inc STOK.OQ reported a quarterly adjusted loss of 40 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -46 cents. The mean expectation of ten analysts for the quarter was for a loss of 51 cents per share. Wall Street expected results to range from -68 cents to -3 cents per share.

• Revenue rose 186% to $13.82 million from a year ago; analysts expected $8.91 million.

• Stoke Therapeutics Inc's reported EPS for the quarter was a loss of 40 cents​.

• The company reported a quarterly loss of $23.48 million.

• Stoke Therapeutics Inc shares had risen by 15.9% this quarter and gained 19.3% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 11.8% in the last three months.​

• In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Stoke Therapeutics Inc is $22.00, about 40.2% above its last closing price of $13.16

This summary was machine generated from LSEG data August 12 at 08:44 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)